Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 5 institutions in 2 countries.
Avery C LeeCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9754-7245
Sai Ravi PingaliCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Javier A Pinilla-IbarzDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Michael L AtchisonDepartment of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Constantinos KoumenisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yair ArgonDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Andrei Thomas-TikhonenkoDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2739-2206
Chih-Chi Andrew HuCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA. cahu@houstonmethodist.org.ORCID http://orcid.org/0000-0001-9024-2932
Chih-Hang Anthony TangCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA. catang@houstonmethodist.org.ORCID http://orcid.org/0000-0002-5097-5709
Houston Methodist · USChildren's Hospital of Philadelphia · USUniversity of Pennsylvania · USMoffitt Cancer Center · USVrije Universiteit Brussel · BE
Funding
Targeting ER stress response in B-cell chronic lymphocytic leukemiaR01CA163910 · NCI · WISTAR INSTITUTE · PI Chih-Chi Andrew Hu · 2013 to 2026
$4.8M
Cassette exons in neoplastic pro-B-cells: implications for immunotherapyU01CA232563 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI BARASH, YOSEPH, THOMAS-TIKHONENKO, ANDREI · 2018 to 2022
$3.5M
XBP1 Inhibition and STING activation for the treatment of cancerR01CA268340 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Juan R Del Valle, Chih-Chi Andrew Hu · 2022 to 2026
$2.8M
Mechanisms of lineage plasticity revealed by YY1 deficiency.R01AI162879 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ATCHISON, MICHAEL LEE · 2021 to 2025
$2.5M
YY1-dependent chromatin structure stabilization of B lineage commitmentR01AI155540 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ATCHISON, MICHAEL LEE · 2021 to 2025
$2.5M
The immunosuppressive function of secretory IgM in tumor-bearing miceK22CA248354 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI TANG, CHIH-HANG ANTHONY · 2021 to 2023
$583k
African trypanosome parasites: a new tool to unveil potential immunological strategies to target CLLR21CA259345 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI DE TREZ, CARL, HU, CHIH-CHI ANDREW · 2021 to 2021
Activation-induced cytidine deaminase (AID) has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it plays in the development and progression of this disease is still unclear. We generated an AID knockout CLL mouse model, AID
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Loss of AID exacerbates the malignant progression of CLL. · full record | Socratic